{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T18:48:53Z","timestamp":1773427733029,"version":"3.50.1"},"reference-count":0,"publisher":"African Journals Online (AJOL)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Afr H. Sci."],"abstract":"<jats:p>Background: Drugs that are used in COVID-19 infection, may interact with each other, as well as with the drugs for comorbidities, used concomitantly with COVID-19 treatment.\r\nObjectives: It is quite important to calculate and present the patients\u2019 exposure to clinically important potential drug-drug interactions (pDDIs). We aimed to investigate the pDDIs and the burden of polypharmacy in COVID-19.\r\nMethods: The medical records of 126 consecutive inpatients with COVID-19 treatment were retrospectively analyzed. The Lexi-interact database was used to investigate pDDIs.\r\nResults: According to the Lexi-interact database, 605 pDDIs were detected. Of these pDDIs, 23 (3.8%) were A risk category interaction, 186 (30.7%) were B risk category interaction, 339 (56%) were C risk category interaction, 54 (8.9%) were D risk category interaction, and 3 (0.5%) were X risk category interaction. Sixty-five-point five percent of pDDIs (n=396) were clinically important pDDIs (C, D, and X categories), and 69 patients (54.8%) had at least one clinically important pDDIs. The most interacting drug was hydroxychloroquine (n=171, 28.3%). Hydroxychloroquine was also the most interacting drug in the C risk category (n=101, 29.8%) and had 19 pDDIs with metformin, 16 pDDIs with beta-blockers, 13 pDDIs with acetylsalicylic acid, and 10 pDDIs with insulin in the C risk category. Enoxaparin was the most interacting drug (n=25, 46.3%) in the D risk category and most of them were with acetylsalicylic acid (n=12). The most common possible clinical manifestations of pDDIs were QT prolongation, hypoglycemia, and hemorrhage. One hundred and eighteen patients (93.6%) used five or more drugs daily. There was a significant positive correlation between the number of drugs prescribed to patients and the number of clinically important pDDIs (r=0.80, p&lt;0.001).\r\nConclusions: Clinically important pDDIs are common among COVID-19 patients and the majority of pDDIs require monitoring of therapy. COVID-19 patients should be closely observed for QT prolongation, hypoglycemia, and hemorrhage due to pDDIs during treatment.\r\nKeywords: COVID-19; drug interactions; polypharmacy.<\/jats:p>","DOI":"10.4314\/ahs.v22i4.65","type":"journal-article","created":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T12:56:49Z","timestamp":1677848209000},"page":"597-606","source":"Crossref","is-referenced-by-count":6,"title":["Evaluation of potential drug-drug interactions and polypharmacy in hospitalized COVID-19 patients"],"prefix":"10.4314","volume":"22","author":[{"given":"T\u00fcrkan","family":"Pa\u015fal\u0131 Kilit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filiz","family":"\u00d6zyi\u011fit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serta\u015f","family":"Erarslan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevser","family":"Onba\u015f\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2895","published-online":{"date-parts":[[2022,12,25]]},"container-title":["African Health Sciences"],"original-title":[],"link":[{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/238943\/225832","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/download\/238943\/225832","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,3]],"date-time":"2023-03-03T12:57:17Z","timestamp":1677848237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ajol.info\/index.php\/ahs\/article\/view\/238943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,25]]},"references-count":0,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,12,28]]}},"URL":"https:\/\/doi.org\/10.4314\/ahs.v22i4.65","relation":{},"ISSN":["1729-0503","1680-6905"],"issn-type":[{"value":"1729-0503","type":"electronic"},{"value":"1680-6905","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12,25]]}}}